Swiss biotech Windward Bio is planning to take on some heavyweight rivals with its TSLP-acting drug for inflammatory ...

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "TSLP Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic information on approved drugs and drug ...

Please provide your email address to receive an email when new articles are posted on . Patients with asthma saw a 23% reduction in FeNO with treatment. Most adverse events were mild, with no serious ...

Windward Bio is in full sail with a $165 million crossover financing to push its long-acting anti-TSLP antibody into phase 3, betting that a twice-yearly dosing schedule will be a key differentiator ...

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "TSLP Inhibitors and TSLP Receptor Antagonists: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering. This competitive ...

Please provide your email address to receive an email when new articles are posted on . The treatment group had reductions in FeNO 1 week after a single dose. Reductions were significant compared with ...

Upstream Bio Inc. (NASDAQ:UPB) is one of the best hot stocks to invest in. On September 30, Upstream Bio presented new structural and mechanistic data for its therapeutic candidate, verekitug, at the ...

Generate Biomedicines Inc. proved that enthusiasm hasn’t waned for TSLP as a target by pricing an IPO selling 25 million shares at $16 each for proceeds of $400 million. Generate’s lead compound is ...